20mins delayed


1 Year Return

Next Science Ltd Chart

Share price
Market Cap $146.84 million
Today's Movement
Prev. Close
Day Range -
Historical Stats
52w Range -
4w Avg Volume
4w Avg Turnover

NXS Statistics

27 November

745 / 2,246

ASX Size Rank

1yr Return

vs Sector (1yr)


vs ASX 200 (1yr)


$146.84 million

Market Cap

Share Issue

121.35 million

All Ords (%)


Short Sold


Current Fundamentals

27 November


PE Ratio

EPS ($)


Earnings Yield


NTA ($)



Dividend Yield

DPS ($)


Gross Div. Yield


Gross DPS ($)


Company Overview

Next Science Limited (NXS) is a medical technology with a research and development centre in Florida, USA. NXS has four FDA cleared products currently available in the US market to treat and manage surgical site infections and chronic wounds.

Next Science Ltd Logo

Corporate Details

Head Office: Chatswood
Managing Director: Judith Mitchell
GICS Sub-Industry: Health Care Supplies
Date Listed: 18 Apr 2019
Registry: Link Market Services
Similar Companies: FPH / COH / RMD / ANN / NAN

Upcoming Calendar

26 Feb 2021 Report (Prelim)
8 Apr 2021 Report (Annual)
25 Aug 2021 Report (Interim)

Dividend History

Ex-Date Amount Franking Type Payable
No dividends paid in the last 5 years

See Upcoming Dividends for all ASX companies.


Date Heading Pages File Size Time

Announcements provided by

Broker Consensus

The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.









Broker Consensus data compiled by Market Index.

Directors & Management

About the Data

Name Title Since Bio
Mr Mark Raymond Compton Non-Executive Director Oct 2018
Mr George Savvides Non-Executive Chairman, Non-Executive Director Jul 2018
Mr Bruce Alan Hancox Non-Executive Director Oct 2017
Mr Dan Spira Non-Executive Director Oct 2017
Mrs Aileen Stockburger Non-Executive Director Oct 2018
Ms Judith Mitchell Managing Director Oct 2017
Jacqueline Butler Chief Financial Officer N/A
Jon Swanson Chief Operating Officer N/A
Matthew Myntti Chief Technology Officer N/A
Gillian Maria Nairn Company Secretary N/A

Director Transactions

About the Data

NXS directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
29/10/20 Judith Mitchell Buy +178,200 $1.155 $205,755 On-market trade.
29/10/20 Judith Mitchell Buy +22,438 $1.155 $25,907 On-market trade.
28/10/20 Bruce Hancox Buy +30,000 $1.160 $34,800 On-market trade.
19/10/20 Mark Compton Buy +12,438 $1.180 $14,676 Participation in share purchase plan.
19/10/20 George Savvides Buy +24,876 $1.180 $29,353 Participation in share purchase plan.
19/10/20 Judith Mitchell Buy +12,438 $1.180 $14,676 Participation in share purchase plan.
02/10/20 Bruce Hancox Buy +154,330 $1.240 $191,369 On-market trade.
24/09/20 Bruce Hancox Buy +70,000 $1.240 $86,800 On-market trade.
24/09/20 Bruce Hancox Buy +145,670 $1.206 $175,707 On-market trade.
06/05/20 Dan Spira Issued 12,537 $1.990 $24,948 Director remuneration.
06/05/20 Aileen Stockburger Issued 11,283 $1.990 $22,453 Director remuneration.
19/12/19 Dan Spira Issued 8,865 $2.820 $24,999 Director remuneration.
19/12/19 Aileen Stockburger Issued 7,977 $2.820 $22,495 Director remuneration.
25/09/19 Dan Spira Issued 27,864 $1.674 $46,643 Director remuneration.
25/09/19 Aileen Stockburger Issued 25,577 $1.661 $42,475 Director remuneration.

Shareholder Distribution

Shareholder Distribution data is unavailable.

Top 20 Shareholders

No data available. Most companies release Top 20 Shareholders data in their Annual Report but it's not compulsory.

NXS Share Price History

Date Close Change % Change Open High Low Volume Turnover

NXS Historical Data

Download up to 20 years of share price history.

Year Closing Price (30 June) Last Trade
2020 $1.25 30 June
2019 $4.11 28 June
2014 $0.013 30 June

Offical data as published by ASX. See more Data Downloads.

Company Details

Principal Activity: Research, development and commercialisation of technologies which solve issues in human health caused by biofilms.

Incorporated: --

Suite 1902, Level 19, Tower A The Zenith Building, 821 Pacific Hwy
Chatswood NSW 2067

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.